Tag: Eczema

1. Upadacitinib combined with topical corticosteroids reduced Eczema Area and Severity Index (EASI) and Investigator’s Global Assessment for atopic dermatitis (vIGA-AD) scores significantly more than placebo with corticosteroids. 2. Efficacy of upadacitinib combination therapy was comparable to upadacitinib monotherapy, suggesting potential for steroid-sparing treatment of atopic dermatitis. Evidence Rating Level: 1...
1. The proportion of patients with EASI ≥75% was significantly greater in the upadacitinib 30 mg and 15 mg groups than the placebo group. 2. Both upadacitinib doses were well tolerated, with the most common adverse events being acne and upper respiratory tract infection. Evidence Rating Level: 1 (Excellent) Study Rundown: Upadacitinib...
1. Individuals diagnosed with atopic dermatitis (AD) as children were at elevated risk of not attaining lower and upper secondary education, compared to the general population, although this association was not present for university education. 2. No difference in educational attainment was found when children with AD were compared to...
1. In this study, nemolizumab with topical agents and oral antihistamines when compared to topical agents and oral antihistamines alone reduced pruritis in atopic dermatitis patients 2. Among patients in the nemolizumab group, eczema area, quality of life and insomnia improved when compared with placebo. Evidence Rating Level: 1 (Excellent) Study Rundown:...
1. In treatment-resistant childhood atopic dermatitis, omalizumab significantly reduced the severity of dermatitis and improved quality of life compared to placebo.  Evidence Rating Level: 1 (Excellent) Anti-IgE medications such as omalizumab are well-tolerated in patients with severe asthma and atopy; however, no large randomized trials have examined its efficacy in children experiencing...
1. In treatment-resistant childhood atopic dermatitis, omalizumab significantly reduced the severity of dermatitis and improved quality of life compared to placebo.  Evidence Rating Level: 1 (Excellent) Anti-IgE medications such as omalizumab are well-tolerated in patients with severe asthma and atopy; however, no large randomized trials have examined its efficacy in children...
PD-1 blockade in advanced adrenocortical carcinoma 1. Pembrolizumab may provide clinically meaningful anti-tumor activity in the setting of adrenocortical carcinoma, particularly in tumors characterized by microsatellite instability and/or mismatch repair  Evidence Rating Level: 2 (Good) Adrenocortical carcinomas (ACC) are rare and typically carry a poor prognosis, with the majority of patients presenting...
Atopic dermatitis, a common disorder in the pediatric population, is associated with pruritus that is often worse at night and, thus, can interfere with sleep. This longitudinal cohort study aimed to assess whether active atopic dermatitis impacts sleep duration and quality, and to examine the association between severity of...
1. The results of this study suggested that the prevalence of atopic dermatitis increased with age among a U.K. adult primary care population. 2. The rates of active eczema were found to be highest among children and older adults. Evidence Rating Level: 2 (Good) Study Rundown: Atopic dermatitis, more commonly known as...
 1. The majority of patients using pimecrolimus cream (PIM, 52.6%) or topical corticosteroids (TCS, 50.5%) for the treatment of mild to moderate atopic dermatitis were cleared of manifestations of the disease by week 3 of use. 2. No significant differences in adverse effects and safety or changes in immunity were...